Astellas Pharma officially opened its Astellas Life Sciences Center to foster pioneering science through collaboration with external partners. According to the company, approximately 400 Astellas employees will operate out of the new building, representing Medical & Development, Business Development and Research.
“Our new Astellas Life Sciences Center and open innovation SakuLab will advance our efforts to deliver breakthrough therapies and novel modalities, with a focus on areas of high unmet need,” said Tadaaki Taniguchi, M.D., Ph.D., Chief Medical Officer, Astellas. “It will also strengthen our partnerships with local academic institutions and biotech innovators, underpinning our commitment to pursue transformative treatments in oncology, ophthalmology and rare diseases for patients in need.”
The new Cambridge facility is part of Astellas’ growing presence in Massachusetts. In 2020, the company launched the Astellas Institute of Regenerative Medicine (AIRM) located in Westborough, Mass., as a global hub for pioneering the development of regenerative medicine and cell-based therapies. Through its Tax Incentive program, the MLSC has previously awarded $1,282,605 to Astellas toward the creation of 85 jobs.
